<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420003</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-GNE-07222011</org_study_id>
    <nct_id>NCT01420003</nct_id>
  </id_info>
  <brief_title>Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics</brief_title>
  <official_title>Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the time course of B cell activation after
      allergen challenge, and more specifically measure the M1 prime related biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      M1 prime is a segment of IgE found only in the membrane form of IgE and not on soluble IgE
      found in serum. Membrane IgE (and M1prime) is expressed on IgE-switched B cells, IgE-memory B
      cels, and IgE-plasmablasts. Depletion of IgE-switched B cells and plasmablasts will reduce
      IgE-producing cells and serum IgE, and may be a target for treatment of allergic asthma. A
      humanized antibody targeting M1 prime is being developed by Genentech, Inc., as a potential
      therapeutic for asthma.

      Currently, the efficacy of MEMP1972A is being assessed in an allergen challenge study in mild
      asthmatics (MOP4843g). Extensive biomarker samples have been incorporated in that study to
      characterize the mechanism of action (MOA) as well as the kinetics of the MOA of MEMP1972A,
      which are poorly understood at this time. Furthermore, samples for the B cell enriched
      peripheral blood flow cytometry and bone marrow aspirates to evaluate the kinetics and MOA of
      MEMP1972a are collected only 24 hr after allergen challenge due to visit and sample volume
      limitations. It is known that maximal B cell responses are expected ~7 days after allergen
      stimulation. Therefore, the purpose of this research study will be to characterize the time
      course of B cell activation after allergen challenge, and more specifically measure the M1
      prime related biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.</measure>
    <time_frame>Within 7 days of allergen challenge</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Atopic Asthma</condition>
  <arm_group>
    <arm_group_label>Allergen Challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Aspiration</intervention_name>
    <description>3 per study</description>
    <arm_group_label>Allergen Challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tonsil Biopsy</intervention_name>
    <description>Optional upon completion of study</description>
    <arm_group_label>Allergen Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers 18 through 65 years of age.

          -  Females must not be actively seeking pregnancy, must be using adequate and effective
             contraception

          -  General good health

          -  Mild to moderate, stable, allergic asthma

          -  History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of
             the predicted value

          -  Able to understand and give written informed consent and has signed a written informed
             consent form approved by the investigator's REB

          -  Positive methacholine challenge

          -  Positive skin-prick test to common aeroallergens (including cat, dust mite, grass,
             pollen)

          -  Positive allergen-induced airway bronchoconstriction (a fall in FEV1 of at least 20%
             from baseline)

        Exclusion Criteria:

          -  A worsening of asthma or a respiratory tract infection within 6 weeks preceding study
             entry

          -  History of clinically significant hypotensive episodes or symptoms of fainting,
             dizziness, or lightheadedness

          -  History or symptoms of clinically significant autoimmune disease

          -  History of clinically significant hematologic abnormality, including coagulopathy

          -  Be pregnant or lactating

          -  Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin)
             within 28 days prior to randomization into the study

          -  Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of dosing or
             aspirin with 7 days of dosing

          -  Have chronic use of any other medication for treatment of allergic lung disease other
             than short- and intermediate-acting ß2-agonists or ipratropium bromide

          -  Use of caffeine-containing products or medications for 12 hours or alcohol or over the
             counter drugs including aspirin, cold and allergy medications for 48 hours or inhaled
             bronchodilators for 8 hours prior to methacholine and allergen challenges

          -  Use of tobacco products of any kind currently or within the previous 12 months, or
             smoking history &gt; 10 pack years.

          -  Lung disease other than mild to moderate allergic asthma

          -  Unwillingness or inability to comply with the study protocol for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail M Gauvreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardio- Respiratory Research Laboratory, Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://fhs.mcmaster.ca/crlab/</url>
    <description>McMaster Cardio Respiratory Laboratory Site</description>
  </link>
  <reference>
    <citation>Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008 Jan;31(1):143-78. doi: 10.1183/09031936.00138707. Erratum in: Eur Respir J. 2018 Jan 31;51(2):.</citation>
    <PMID>18166595</PMID>
  </reference>
  <reference>
    <citation>National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. Erratum in: J Allergy Clin Immunol. 2008 Jun;121(6):1330.</citation>
    <PMID>17983880</PMID>
  </reference>
  <reference>
    <citation>Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy. 1993 Nov;23(11):941-8.</citation>
    <PMID>10779282</PMID>
  </reference>
  <reference>
    <citation>Boulet LP, Cartier A, Thomson NC, Roberts RS, Dolovich J, Hargreave FE. Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure. J Allergy Clin Immunol. 1983 Apr;71(4):399-406.</citation>
    <PMID>6601124</PMID>
  </reference>
  <reference>
    <citation>Antó JM, Sunyer J, Rodriguez-Roisin R, Suarez-Cervera M, Vazquez L. Community outbreaks of asthma associated with inhalation of soybean dust. Toxicoepidemiological Committee. N Engl J Med. 1989 Apr 27;320(17):1097-102.</citation>
    <PMID>2710172</PMID>
  </reference>
  <reference>
    <citation>O'Hollaren MT, Yunginger JW, Offord KP, Somers MJ, O'Connell EJ, Ballard DJ, Sachs MI. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med. 1991 Feb 7;324(6):359-63.</citation>
    <PMID>1987459</PMID>
  </reference>
  <reference>
    <citation>Bellomo R, Gigliotti P, Treloar A, Holmes P, Suphioglu C, Singh MB, Knox B. Two consecutive thunderstorm associated epidemics of asthma in the city of Melbourne. The possible role of rye grass pollen. Med J Aust. 1992 Jun 15;156(12):834-7.</citation>
    <PMID>1603007</PMID>
  </reference>
  <reference>
    <citation>Platts-Mills TA, Tovey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982 Sep 25;2(8300):675-8.</citation>
    <PMID>6126624</PMID>
  </reference>
  <reference>
    <citation>HERXHEIMER H. The late bronchial reaction in induced asthma. Int Arch Allergy Appl Immunol. 1952;3(4):323-8.</citation>
    <PMID>13044326</PMID>
  </reference>
  <reference>
    <citation>O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987 Sep;136(3):740-51. Review.</citation>
    <PMID>3115156</PMID>
  </reference>
  <reference>
    <citation>O'Byrne PM, Wood L. Interleukin-5 and allergic inflammation. Clin Exp Allergy. 1999 May;29(5):573-5.</citation>
    <PMID>10231314</PMID>
  </reference>
  <reference>
    <citation>Kloek J, Mortaz E, van Ark I, Lilly CM, Nijkamp FP, Folkerts G. Glutathione prevents the early asthmatic reaction and airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2010 Feb;61(1):67-72.</citation>
    <PMID>20228417</PMID>
  </reference>
  <reference>
    <citation>Becker AB, Black C, Lilley MK, Bajwa K, Ford-Hutchinson AW, Simons FE, Tagari P. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs. J Appl Physiol (1985). 1995 Feb;78(2):615-22.</citation>
    <PMID>7759431</PMID>
  </reference>
  <reference>
    <citation>Coyle AJ, Page CP, Atkinson L, Flanagan R, Metzger WJ. The requirement for platelets in allergen-induced late asthmatic airway obstruction. Eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis. 1990 Sep;142(3):587-93.</citation>
    <PMID>2389910</PMID>
  </reference>
  <reference>
    <citation>Hamel R, McFarlane CS, Ford-Hutchinson AW. Late pulmonary responses induced by Ascaris allergen in conscious squirrel monkeys. J Appl Physiol (1985). 1986 Dec;61(6):2081-7.</citation>
    <PMID>3804916</PMID>
  </reference>
  <reference>
    <citation>Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17.</citation>
    <PMID>8756799</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Gail Gauvreau</investigator_full_name>
    <investigator_title>Gail Gauvreau, PhD</investigator_title>
  </responsible_party>
  <keyword>Allergen Challenge</keyword>
  <keyword>B cell activation</keyword>
  <keyword>M1 prime related biomarkers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

